MSB 7.69% $1.19 mesoblast limited

Mesoblast is well advanced in its phase 3 trial for treatment of...

  1. 349 Posts.
    lightbulb Created with Sketch. 7
    Mesoblast is well advanced in its phase 3 trial for treatment of Crohn's disease and is way ahead of TiGenix which as not commenced a phase 3 trial in the US. Mesoblast is the leader in this field when it comes to Patents and trial time frames completion.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.